Sécurité cardiovasculaire des antidiabétiques [Cardiovascular safety of antidiabetics]

Details

Serval ID
serval:BIB_352459C4E3D5
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Sécurité cardiovasculaire des antidiabétiques [Cardiovascular safety of antidiabetics]
Journal
Revue medicale suisse
Author(s)
Aline Roth P.W., Jornayvaz F.R.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
01/06/2016
Peer-reviewed
Oui
Volume
12
Number
521
Pages
1084,1086-1088
Language
french
Notes
Publication types: English Abstract ; Journal Article ; Review
Publication Status: ppublish
Abstract
Type 2 diabetes is characterized by a high risk of micro- and macro-vascular complications. Cardiovascular diseases are the leading cause of death of diabetic patients. In this context, the search for molecules decreasing cardiovascular mortality makes sense. Until the EMPA-REG OUTCOME study published late 2015, showing a reduction of cardiovascular mortality of patients treated with empagliflozin, an SGLT2 inhibitor, there was no molecule known to decrease cardiovascular mortality. The purpose of this article is to review the various existing antidiabetic molecules and their impact (positive/neutral/negative) on cardiovascular mortality.

Keywords
Cardiovascular Diseases/etiology, Cardiovascular Diseases/mortality, Cardiovascular Diseases/prevention & control, Diabetes Mellitus, Type 2/complications, Diabetes Mellitus, Type 2/drug therapy, Humans, Hypoglycemic Agents/therapeutic use, Randomized Controlled Trials as Topic
Pubmed
Create date
13/09/2016 13:32
Last modification date
20/08/2019 13:22
Usage data